Safety surveillance of esterified estrogens-methyltestosterone (Estratest® and Estratest® HS) replacement therapy in the United States

Clinical Therapeutics

Volumn 19, Issue 5, 1997, Pages 1070-1084

  Phillips, Eric ^a   Bauman, Carl ^a  

^a Solvay Pharmaceuticals Inc   (Netherlands)

Author keywords

Androgen; Estrogen; Hormone replacement therapy; Pharmacovigilance; Safety surveillance

Indexed keywords

ESTRATEST; ESTROGEN; METHYLTESTOSTERONE; UNCLASSIFIED DRUG;

ARTHRALGIA; ARTICLE; CARDIOVASCULAR DISEASE; DRUG FORMULATION; DRUG MARKETING; DRUG MONITORING; DRUG SAFETY; ESTROGEN THERAPY; GASTROINTESTINAL TOXICITY; HEADACHE; HOSTILITY; HUMAN; LARYNX DISORDER; LIVER DYSFUNCTION; NEUROTOXICITY; SKIN TOXICITY; THROMBOEMBOLISM;

EID: 0030719423     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(97)80060-4     Document Type: Article

References (17)

1. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary artery disease: A quantitative assessment of the epidemiologic evidence. Prev Med. 1991;20: 47-63.
2. Raisz LG, Wiita B, Artis A, et al. Comparison of the effects of estrogen alone and estrogen plus androgen on biochemical markers of bone formation and resorption in postmenopausal women. J Clin Endocrinol Metab. 1996;81:37-43.
3. Watts NB, Notelovitz M, Timmons MC, et al. Comparison of oral estrogens and estrogens plus androgen on bone mineral density, menopausal symptoms, and lipidlipoprotein profiles in surgical menopause. Obstet Gynecol. 1995;85:529-537.
4. Smith DC, Prentice R, Thompson DJ, et al. Association of exogenous estrogens and endometrial carcinoma. NEJM. 1975; 293:1164.
5. Bagatell CJ, Bremner WJ. Androgens in men - uses and abuses. NEJM. 1996;334: 707-714.
6. Bhasin S, Storer TW, Berman N, et al. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. NEJM. 1996;335:1-7.
7. Nachtigall LE, Nachtigall RH, Nachtigall RD, et al. Estrogen replacement therapy II: A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstet Gynecol. 1979;54: 74-79.
8. Ishak KG, Zimmerman HJ. Hepatotoxic effects of the anabolic/androgenic steroids. Semin Liver Dis. 1987;7:230-236.
9. Barrett-Connor E, Timmons C, Young R, et al. Interim safety analysis of a two-year study comparing oral estrogen-androgen and conjugated estrogens in surgically menopausal women. J Women's Health. 1996;5:593-602.
10. Gelfand MM, Wiita B. Androgen and estrogen-androgen hormone replacement therapy: A review of the safety literature 1941-1996. Clin Ther. 1997;19:383-404.
11. Cerrito PB, Cerrito JC. Assessing risk in postmarketing surveillance. J Biopharm Stat. 1991;1:221-235.
12. Edlavitch SA. Postmarketing surveillance methodologies. Drug Intell Clin Pharm. 1988;22:68-78.
13. Fletcher AP. Spontaneous adverse drug reaction reporting vs. event monitoring: A comparison. J R Soc Med. 1991;84: 341-344.
14. Furst DE. Comparing the strengths and weaknesses of observational and experimental studies using a postmarketing surveillance study as a prototypic example. Semin Arthritis Rheum. 1993;23(Suppl 1): 57-61.
15. Grady D, Gebretsadik T, Kerlikowske K, et al. Hormone replacement therapy and endometrial cancer risk: A meta-analysis. Obstet Gynecol. 1995;85:304-313.
16. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. NEJM. 1995;332: 1589-1593.
17. The Coronary Drug Project Research Group. The coronary drug project: Findings leading to discontinuation of the 2.5 mg/day estrogen group. JAMA. 1973;226: 652-657.